Remote genetic counseling with optional digital tools for hereditary cancer testing
Official title: Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)
Run by Abramson Cancer Center at Penn Medicine · NCT07471958 · Data updated 2026-11-12
This project will test telehealth and optional digital tools to deliver pre-test education and result disclosure for adults who qualify for hereditary cancer genetic testing.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 360 (estimated) |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | September 2, 2025 |
| Main results expected | March 2029 |
| Study ends | March 2029 |
| Registry record updated | March 13, 2026 |
| Trial ID | NCT07471958 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who speak and understand English and who meet NCCN or other national criteria for germline genetic testing, or who seek genetic counseling based on personal or family cancer history, are ideal candidates.
✕Probably not a fit
Patients with uncorrected or uncompensated hearing, vision, or speech impairments, uncontrolled psychiatric illness, or severe cognitive deficits that prevent participation may not benefit from the telehealth and digital approaches.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The eREACH3 project observes how telehealth genetic counseling and optional digital tools are used as alternatives to the traditional two-visit genetic counseling model. Participants initially receive two remote genetic counseling visits and may be offered optional digital supports for education and result disclosure. The study will track uptake, patterns of tool use, and patient-reported cognitive, emotional, and behavioral outcomes at short-term and six-month follow-up. It will also measure provider time and identify barriers and facilitators to integrating these remote approaches into routine clinical care.
Why it matters
Potential benefit: If successful, this could make genetic counseling more convenient and expand access by offering counseling at home with helpful digital supports.
How similar studies have gone: Previous research has shown telehealth genetic counseling can yield patient outcomes and satisfaction comparable to in-person care, though broad implementation using multiple optional digital tools is less well tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Speak and understand English * Meet current National Comprehensive Cancer Network (NCCN) or other national guidelines for germline genetic testing or are interested in genetic counseling based on personal or family history of cancer. Patients with prior genetic testing are eligible if they meet criteria for updated testing, or if post-test genetic counseling services are requested. Exclusion Criteria: * Communication difficulties such as: * Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded. * Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded. * Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks
Where it's running
-
Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Angela Bradbury, MD — University of Pennsylvania
- Study coordinator: Angela Bradbury, MD
- Email: angela.bradbury@pennmedicine.upenn.edu
- Phone: 215-615-3341
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
DNP-MRSI to predict HCC treatment response
This study tests whether DNP-MRSI imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism in liver tumors can indicate which BCLC A–C HCC lesions will respond after locoregional therapies or systemic treatment.
-
Pemefolacianine imaging for lung cancer surgery
A first-in-human dose study tests a new fluorescent imaging agent given before lung cancer surgery to see if it is safe and helps highlight tissue during thoracoscopy or robotic surgery.
-
Low Dose Radiotherapy for Osteoarthritis
This study tests whether low-dose radiotherapy can help reduce pain and improve function for adults with osteoarthritis who have not benefited from standard treatments.
-
TumorGlow use during surgery to see sarcoma lung metastases in children
This pediatric study tests a single 5 mg/kg dose of TumorGlow (ICG) given before surgery to help doctors see sarcoma metastases in the lungs during tumor removal.
-
Lifestyle and energy balance in breast cancer survivorship
This study tests how diet, physical activity, and urinary metabolites relate to lifestyle changes in women newly diagnosed with breast cancer during treatment and survivorship.
-
Radiation, Vancomycin, and CAR-T for B-Cell Lymphoma
This trial tests if giving radiation and the antibiotic vancomycin before CAR-T cell therapy is feasible for adults with large B-cell lymphomas.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.